Zacks Investment Research on MSN19h
Here's How to Play JNJ Stock as it Announces $55B US Investment PlanJ&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback